Nordic Nanovector to present preclinical study of Betalutin® effect on NHL cells at European Hematology Association meeting

Oslo, Norway, 31 May 2018

Nordic Nanovector ASA (OSE: NANO) announces that it will present a poster describing a preclinical analysis of genetic factors that correlate with the responsiveness of non-Hodgkin’s lymphoma (NHL) cell lines to Betalutin® (177Lu-lilotomab satetraxetan) at the 23rd annual meeting of the European Hematology Association (EHA) (Stockholm, Sweden, 14-17 June). This preclinical study highlights the generally promising activity of Betalutin® against diffuse large B-cell lymphoma (DLBCL) cell lines.

The abstract is available online (click here) and the poster will be available on the company's website at: www.nordicnanovector.com following the presentation on 15 June.

Poster details

Abstract  PF642

Abstract title:  Systems biology analysis of responsiveness of non-Hodgkin lymphoma B-cell lines to CD37 targeting radioimmunotherapy

Authors: Melhus, KB et al.

Date:   Friday 15 June

Time:   17:30-19:00 (CEST)

For further information, please contact:

Malene Brondberg, VP, Investor Relations and Corporate Communications

Tel/Cell: + 44 7561 431 762

Email: ir@nordicnanovector.com

Media enquiries:

Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: nordicnanovector@citigatedr.co.uk  

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information about the Company can be found at www.nordicnanovector.com 

 

Tags:

About Us

About Nordic Nanovector ASA Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.Further information about the Company can be found at www.nordicnanovector.com

Subscribe